Erratum: Transporters as drug targets: Discovery and development of NPC1L1 inhibitors (Clinical Pharmacology and Therapeutics (2010) 87 (117-121) doi:10.1038/clpt.2009.209);Transporters as drug targets: Discovery and development of NPC1L1 inhibitors

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 1, 2010, Pages 117-121

  Betters, J L ^a   Yu, L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVE 5530; CHOLESTEROL; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; NIEMANN PICK C1 LIKE 1 PROTEIN; NIEMANN PICK C1 LIKE 1 PROTEIN INHIBITOR; PROTEIN INHIBITOR; SIMVASTATIN; UNCLASSIFIED DRUG;

ALCOHOLIC FATTY LIVER; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG TARGETING; GALLSTONE FORMATION; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; SHORT SURVEY; UNSPECIFIED SIDE EFFECT;

EID: 72849142291     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.53     Document Type: Erratum

References (32)

1. Chang, T.Y., Chang, C.C., Ohgami, N. & yamauchi, Y. Cholesterol sensing, trafcking, and esterifcation. Annu. Rev. Cell Dev. Biol. 22, 129-157 (2006).
2. Davis, H.R. & Veltri, E.P. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J. Atheroscler. Thromb. 14, 99-108 (2007).
3. Clader, J.W. The discovery of ezetimibe: a view from outside the receptor. J. Med. Chem. 47, 1-9 (2004).
4. Kosoglou, T., Statkevich, P. , johnson-Levonas, A.O., Paolini, J.F., Bergman, A.J. & alton, K.B. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet. 44, 467-494 (2005).
5. van Heek, M. et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br. J. Pharmacol. 129, 1748-1754 (2000).
6. Dawson, P.A. et al. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J. Biol. Chem. 278, 33920-33927 (2003).
7. Huf, M.W. et al. Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB. Arterioscler. Thromb. Vasc. Biol. 22, 1884-1891 (2002).
8. Altmann, S.W. et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303, 1201-1204 (2004).
9. Davies, J.P., Levy, B. & Ioannou, Y.A. Evidence for a Niemann-pick C (NPC) gene family: identifcation and characterization of NPC1L1. Genomics 65, 137-145 (2000).
10. Kwon, H.J. et al. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 137, 1213-1224 (2009).
11. Davies, J.P., Scott, C., Oishi, K., Liapis, A. & Ioannou, Y.A. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J. Biol. Chem. 280, 12710-12720 (2005).
12. Yu, L. The structure and function of Niemann-Pick C1-like 1 protein. Curr. Opin. Lipidol. 19, 263-269 (2008).
13. Davis, H.R. Jr. et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem. 279, 33586-33592 (2004).
14. Yu, L. et al. Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J. Biol. Chem. 281, 6616-6624 (2006).
15. yamanashi, Y., Takada, T. & Suzuki, H. Niemann-Pick C1-like 1 overexpression facilitates ezetimibe-sensitive cholesterol and beta-sitosterol uptake in CaCo-2 cells. J. Pharmacol. Exp. Ther. 320, 559-564 (2007).
16. Weinglass, A.B. et al. Madin-Darby canine kidney II cells: a pharmacologically validated system for NPC1L1-mediated cholesterol uptake. Mol. Pharmacol. 73, 1072-1084 (2008).
17. Garcia-Calvo, M. et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA 102, 8132-8137 (2005).
18. Weinglass, A.B. et al. Extracellular loop C of NPC1L1 is important for binding to ezetimibe. Proc. Natl. Acad. Sci. USA 105, 11140-11145 (2008).
19. Brown, J.M., Rudel, L.L. & yu, L. NPC1L1 (Niemann-Pick C1-like 1) mediates sterol-specifc unidirectional transport of non-esterifed cholesterol in Mcardle-RH7777 hepatoma cells. Biochem. J. 406, 273-283 (2007).
20. Larkin, J.M., Brown, M.S., Goldstein, J.L. & anderson, R.G. Depletion of intracellular potassium arrests coated pit formation and receptor-mediated endocytosis in fbroblasts. Cell 33, 273-285 (1983).
21. Valasek, M.A., Weng, J., Shaul, P.W., Anderson, R.G. & Repa, J.J. Caveolin-1 is not required for murine intestinal cholesterol transport. J. Biol. Chem. 280, 28103-28109 (2005).
22. Ge, L. et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab. 7, 508-519 (2008).
23. Temel, R.E. et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J. Clin. Invest. 117, 1968-1978 (2007).
24. Hegele, R.A., Guy, J., Ban, M.R. & Wang, J. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis. 4, 16 (2005).
25. McMasters, D.R. et al. Spiroimidazolidinone NPC1L1 inhibitors. 1: discovery by 3D-similarity-based virtual screening. Bioorg. Med. Chem. Lett. 19, 2965-2968 (2009).
26. Kastelein, J.J. et al.; ENHaNCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431-1443 (2008).
27. Tang, W., Ma, Y. & yu, L. Plasma cholesterol is hyperresponsive to statin in aBCG5/aBCG8 transgenic mice. Hepatology 44, 1259-1266 (2006).
28. Repa, J.J., Berge, K.E., Pomajzl, C., Richardson, J.A., Hobbs, H. & Mangelsdorf, D.J. Regulation of aTP-binding cassette sterol transporters aBCG5 and aBCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 277, 18793-18800 (2002).
29. Tang, W., Ma, Y., Jia, L., Ioannou, Y.A., Davies, J.P. & yu, L. Niemann-Pick C1-like 1 is required for an LXR agonist to raise plasma HDL cholesterol in mice. Arterioscler. Thromb. Vasc. Biol. 28, 448-454 (2008).
30. Zheng, S. et al. Ezetimibe improves high fat and cholesterol diet-induced nonalcoholic fatty liver disease in mice. Eur. J. Pharmacol. 584, 118-124 (2008).
31. Labonté, E.D. et al. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/-mice. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G776-G783 (2008).
32. Wang, H.H., Portincasa, P. , Mendez-Sanchez, N., Uribe, M. & Wang, D.Q. Efect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 134, 2101-2110 (2008).